^
    20d
    Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients (clinicaltrials.gov)
    P2/3, N=20, Not yet recruiting, The Affiliated People's Hospital of Ningbo University | N=60 --> 20
    Enrollment change
    |
    lisaftoclax (APG-2575)
    26d
    DHODH Drives Sunitinib Resistance Via a Non-Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC. (PubMed, Adv Sci (Weinh))
    Lisaftoclax, a small-molecule inhibitor that disrupts the DHODH-TRIM28 interaction, potentiates sunitinib efficacy and exerts a synergistic therapeutic effect. Collectively, our findings identify DHODH as a critical therapeutic target for overcoming sunitinib resistance in RCC and provide a novel strategy for the treatment of RCC.
    Journal
    |
    TRIM28 (Tripartite Motif Containing 28) • TRIM37 (Tripartite Motif Containing 37)
    |
    sunitinib • lisaftoclax (APG-2575)
    1m
    GLORA: Global Trial in APG2575 for Patients With CLL/SLL (clinicaltrials.gov)
    P3, N=400, Recruiting, Ascentage Pharma Group Inc. | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial primary completion date
    |
    lisaftoclax (APG-2575)
    1m
    Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=450, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    1m
    Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=267, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    2ms
    Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=51, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Epidaza (chidamide) • lisaftoclax (APG-2575)
    2ms
    Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients (clinicaltrials.gov)
    P2/3, N=60, Not yet recruiting, The Affiliated People's Hospital of Ningbo University
    New P2/3 trial
    |
    Jakafi (ruxolitinib) • lisaftoclax (APG-2575)
    2ms
    A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=0, Withdrawn, M.D. Anderson Cancer Center | N=24 --> 0 | Trial completion date: Jun 2032 --> Apr 2026 | Initiation date: Aug 2026 --> Apr 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2030 --> Apr 2026
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date
    |
    clonoSEQ®
    |
    cytarabine • pelcitoclax (APG-1252) • lisaftoclax (APG-2575) • fludarabine IV
    3ms
    APG-2575-CN-001: A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, Ascentage Pharma Group Inc. | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    lisaftoclax (APG-2575)
    3ms
    APG2575AC101: Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (clinicaltrials.gov)
    P1/2, N=682, Recruiting, Ascentage Pharma Group Inc. | N=458 --> 682
    Enrollment change
    |
    azacitidine • Nailike (olverembatinib) • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)
    3ms
    Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • Epidaza (chidamide) • lisaftoclax (APG-2575)
    3ms
    The Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients with Indolent Lymphoma (ChiCTR2600121485)
    P4, N=75, Henan Cancer Hospital; Henan Cancer Hospital
    New P4 trial
    |
    Breyanzi (lisocabtagene maraleucel) • lisaftoclax (APG-2575)